001     180727
005     20240229145630.0
024 7 _ |a 10.1126/scitranslmed.abl4106
|2 doi
024 7 _ |a pmid:35857642
|2 pmid
024 7 _ |a 1946-6234
|2 ISSN
024 7 _ |a 1946-6242
|2 ISSN
024 7 _ |a altmetric:132376480
|2 altmetric
037 _ _ |a DKFZ-2022-01518
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Birocchi, Filippo
|0 0000-0002-5214-233X
|b 0
245 _ _ |a Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models.
260 _ _ |a Washington, DC
|c 2022
|b AAAS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1658474241_32181
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a DKFZ-ZMBH Alliance
520 _ _ |a Glioblastoma multiforme (GBM) is the most common and lethal brain tumor characterized by a strongly immunosuppressive tumor microenvironment (TME) that represents a barrier also for the development of effective immunotherapies. The possibility to revert this hostile TME by immunoactivating cytokines is hampered by the severe toxicity associated with their systemic administration. Here, we exploited a lentiviral vector-based platform to engineer hematopoietic stem cells ex vivo with the aim of releasing, via their tumor-infiltrating monocyte/macrophage progeny, interferon-α (IFN-α) or interleukin-12 (IL-12) at the tumor site with spatial and temporal selectivity. Taking advantage of a syngeneic GBM mouse model, we showed that inducible release of IFN-α within the TME achieved robust tumor inhibition up to eradication and outperformed systemic treatment with the recombinant protein in terms of efficacy, tolerability, and specificity. Single-cell RNA sequencing of the tumor immune infiltrate revealed reprogramming of the immune microenvironment toward a proinflammatory and antitumoral state associated with loss of a macrophage subpopulation shown to be associated with poor prognosis in human GBM. The spatial and temporal control of IL-12 release was critical to overcome an otherwise lethal hematopoietic toxicity while allowing to fully exploit its antitumor activity. Overall, our findings demonstrate a potential therapeutic approach for GBM and set the bases for a recently launched first-in-human clinical trial in patients with GBM.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Cusimano, Melania
|b 1
700 1 _ |a Rossari, Federico
|0 0000-0003-4493-6380
|b 2
700 1 _ |a Beretta, Stefano
|0 0000-0003-4375-004X
|b 3
700 1 _ |a Rancoita, Paola M V
|0 0000-0001-9345-691X
|b 4
700 1 _ |a Ranghetti, Anna
|b 5
700 1 _ |a Colombo, Stefano
|b 6
700 1 _ |a Costa, Barbara Maria
|0 P:(DE-He78)2fe44044f40217387daaf299f2eb7340
|b 7
|u dkfz
700 1 _ |a Angel, Peter
|0 P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9
|b 8
|u dkfz
700 1 _ |a Sanvito, Francesca
|0 0000-0002-4046-8420
|b 9
700 1 _ |a Callea, Marcella
|b 10
700 1 _ |a Norata, Rossana
|0 0000-0003-1367-383X
|b 11
700 1 _ |a Chaabane, Linda
|0 0000-0003-2782-9938
|b 12
700 1 _ |a Canu, Tamara
|0 0000-0002-4589-9377
|b 13
700 1 _ |a Spinelli, Antonello
|0 0000-0001-5762-3426
|b 14
700 1 _ |a Genua, Marco
|0 0000-0002-0764-8163
|b 15
700 1 _ |a Ostuni, Renato
|0 0000-0003-0460-3426
|b 16
700 1 _ |a Merelli, Ivan
|0 0000-0003-3587-3680
|b 17
700 1 _ |a Coltella, Nadia
|0 0000-0002-7633-4766
|b 18
700 1 _ |a Naldini, Luigi
|0 0000-0002-7835-527X
|b 19
773 _ _ |a 10.1126/scitranslmed.abl4106
|g Vol. 14, no. 653, p. eabl4106
|0 PERI:(DE-600)2518839-2
|n 653
|p eabl4106
|t Science translational medicine
|v 14
|y 2022
|x 1946-6234
909 C O |o oai:inrepo02.dkfz.de:180727
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)2fe44044f40217387daaf299f2eb7340
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI TRANSL MED : 2021
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-16
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b SCI TRANSL MED : 2021
|d 2022-11-16
920 1 _ |0 I:(DE-He78)A100-20160331
|k A100
|l A100 Signaltransduktion/ Wachstumskontrolle
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A100-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21